CRINETICS PHARMACEUTICALS Trademark

Trademark Overview


On Friday, March 17, 2023, a trademark application was filed for CRINETICS PHARMACEUTICALS with the United States Patent and Trademark Office. The USPTO has given the CRINETICS PHARMACEUTICALS trademark a serial number of 97844252. The federal status of this trademark filing is FIRST EXTENSION - GRANTED as of Thursday, September 12, 2024. This trademark is owned by Crinetics Pharmaceuticals, Inc.. The CRINETICS PHARMACEUTICALS trademark is filed in the Pharmaceutical Products and Computer & Software Services & Scientific Services categories with the following description:

Pharmaceutical preparations for modulating neuropeptides and G-protein coupled receptors (GPCRs); pharmaceutical preparations for use in oncology; pharmaceutical preparations for use in treating endocrine disorders and endocrine related diseases; pharmaceutical preparations for targeting neuropeptide receptors; pharmaceutical preparations for the treatment of cancer, acromegaly, neuroendocrine tumors, Cushing's Disease, hyperinsulinism, carcinoid syndrome, congenital adrenal hyperplasia, hypercalcemia, chronic pain, hyperparathyroidism, polycystic kidney disease, Grave's disease, thyroid eye disease, thyroid ophthalmopathy, diabetes, obesity, insulinoma, hypoglycemia, androgen deficiency, infertility, thyroid cancer, growth hormone deficiency, hypoparathyroidism, nonfunctional pituitary adenomas, polycystic liver disease, and type two diabetes; therapeutic preparations for the treatment of ocular diseases and disorders, metabolic diseases and disorders, hormonal diseases and disorders,...

Medical research services; scientific research and development; pharmaceutical research and development; therapeutic research and development, namely, research and development of therapeutic preparations; research and development in the field of oncology; medical research for treating cancer, endocrine disorders, acromegaly, neuroendocrine tumors, Cushing's Disease, hyperinsulinism, chronic pain, hypercalcemia, hyperparathyroidism, polycystic kidney disease, Grave's disease, thyroid eye disease, thyroid ophthalmopathy, diabetes, obesity, insulinoma, hypoglycemia, androgen deficiency, infertility, thyroid cancer, growth hormone deficiency, hypoparathyroidism, nonfunctional pituitary adenomas, polycystic liver disease, and type two diabetes; pharmaceutical research for treating cancer, endocrine disorders, acromegaly, neuroendocrine tumors, Cushing's Disease, hyperinsulinism, and chronic pain, hypercalcemia, hyperparathyroidism, polycystic kidney disease, Grave's disease, thyroid eye dis...
crinetics pharmaceuticals

General Information


Serial Number97844252
Word MarkCRINETICS PHARMACEUTICALS
Filing DateFriday, March 17, 2023
Status730 - FIRST EXTENSION - GRANTED
Status DateThursday, September 12, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing3 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s)
Published for Opposition DateTuesday, January 30, 2024

Trademark Statements


Description of MarkThe mark consists of the word "CRINETICS" above the word "PHARMACEUTICALS" with a dot and line spirograph design in the shape of a half circle starting above the letter "I" in "CRINETICS" and wrapping around the first letter "C" in "CRINETICS".
Goods and ServicesPharmaceutical preparations for modulating neuropeptides and G-protein coupled receptors (GPCRs); pharmaceutical preparations for use in oncology; pharmaceutical preparations for use in treating endocrine disorders and endocrine related diseases; pharmaceutical preparations for targeting neuropeptide receptors; pharmaceutical preparations for the treatment of cancer, acromegaly, neuroendocrine tumors, Cushing's Disease, hyperinsulinism, carcinoid syndrome, congenital adrenal hyperplasia, hypercalcemia, chronic pain, hyperparathyroidism, polycystic kidney disease, Grave's disease, thyroid eye disease, thyroid ophthalmopathy, diabetes, obesity, insulinoma, hypoglycemia, androgen deficiency, infertility, thyroid cancer, growth hormone deficiency, hypoparathyroidism, nonfunctional pituitary adenomas, polycystic liver disease, and type two diabetes; therapeutic preparations for the treatment of ocular diseases and disorders, metabolic diseases and disorders, hormonal diseases and disorders, reproductive diseases and disorders, bone diseases and disorders, digestive diseases and disorders, gastroenterological diseases and disorders, and thyroid diseases and disorders
Indication of Colors claimedColor is not claimed as a feature of the mark.
NOT AVAILABLEPHARMACEUTICALS
Goods and ServicesMedical research services; scientific research and development; pharmaceutical research and development; therapeutic research and development, namely, research and development of therapeutic preparations; research and development in the field of oncology; medical research for treating cancer, endocrine disorders, acromegaly, neuroendocrine tumors, Cushing's Disease, hyperinsulinism, chronic pain, hypercalcemia, hyperparathyroidism, polycystic kidney disease, Grave's disease, thyroid eye disease, thyroid ophthalmopathy, diabetes, obesity, insulinoma, hypoglycemia, androgen deficiency, infertility, thyroid cancer, growth hormone deficiency, hypoparathyroidism, nonfunctional pituitary adenomas, polycystic liver disease, and type two diabetes; pharmaceutical research for treating cancer, endocrine disorders, acromegaly, neuroendocrine tumors, Cushing's Disease, hyperinsulinism, and chronic pain, hypercalcemia, hyperparathyroidism, polycystic kidney disease, Grave's disease, thyroid eye disease, thyroid ophthalmopathy, diabetes, obesity, insulinoma, hypoglycemia, androgen deficiency, infertility, thyroid cancer, growth hormone deficiency, hypoparathyroidism, nonfunctional pituitary adenomas, polycystic liver disease, and type two diabetes; therapeutic research, namely, research of therapeutic preparations for ocular diseases and disorders, metabolic diseases and disorders, hormonal diseases and disorders, reproductive diseases and disorders, bone diseases and disorders, digestive diseases and disorders, gastroenterological diseases and disorders, and thyroid diseases and disorders; providing medical and scientific research information in the fields of pharmaceuticals and therapeutics

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateSunday, April 9, 2023
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateSunday, April 9, 2023
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameCrinetics Pharmaceuticals, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressSan Diego, CA 92121

Party NameCrinetics Pharmaceuticals, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressSan Diego, CA 92121

Trademark Events


Event DateEvent Description
Tuesday, March 21, 2023NEW APPLICATION ENTERED
Sunday, April 9, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, April 11, 2023NOTICE OF DESIGN SEARCH CODE E-MAILED
Monday, October 9, 2023TEAS VOLUNTARY AMENDMENT RECEIVED
Monday, October 9, 2023PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED
Wednesday, December 13, 2023ASSIGNED TO EXAMINER
Monday, December 18, 2023EXAMINERS AMENDMENT -WRITTEN
Monday, December 18, 2023EXAMINERS AMENDMENT E-MAILED
Monday, December 18, 2023NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Tuesday, December 19, 2023ASSIGNED TO LIE
Tuesday, December 19, 2023EXAMINER'S AMENDMENT ENTERED
Friday, December 22, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, January 10, 2024NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, January 30, 2024PUBLISHED FOR OPPOSITION
Tuesday, January 30, 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Wednesday, February 28, 2024TEAS CHANGE OF CORRESPONDENCE RECEIVED
Wednesday, February 28, 2024APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Wednesday, February 28, 2024TEAS CHANGE OF OWNER ADDRESS RECEIVED
Tuesday, March 26, 2024NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Thursday, September 12, 2024TEAS STATEMENT OF USE RECEIVED
Thursday, September 12, 2024SOU TEAS EXTENSION RECEIVED
Thursday, September 12, 2024SOU EXTENSION 1 FILED
Thursday, September 12, 2024SOU EXTENSION 1 GRANTED
Thursday, September 12, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED